Fortress Biotech/$FBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fortress Biotech
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Ticker
$FBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
101
ISIN
US34960Q3074
Website
Fortress Biotech Metrics
BasicAdvanced
$59M
-
-$2.20
1.77
-
Price and volume
Market cap
$59M
Beta
1.77
52-week high
$2.89
52-week low
$1.33
Average daily volume
169K
Financial strength
Current ratio
1.722
Quick ratio
1.489
Long term debt to equity
216.099
Total debt to equity
228.517
Interest coverage (TTM)
-6.46%
Management effectiveness
Return on assets (TTM)
-32.37%
Return on equity (TTM)
-746.25%
Valuation
Price to revenue (TTM)
0.8
Price to book
2.66
Price to tangible book (TTM)
-6.91
Price to free cash flow (TTM)
-0.506
Growth
Revenue change (TTM)
-32.11%
Earnings per share change (TTM)
-62.69%
3-year revenue growth (CAGR)
-10.69%
3-year earnings per share growth (CAGR)
-45.13%
What the Analysts think about Fortress Biotech
Analyst ratings (Buy, Hold, Sell) for Fortress Biotech stock.
Fortress Biotech Financial Performance
Revenues and expenses
Fortress Biotech Earnings Performance
Company profitability
Fortress Biotech News
AllArticlesVideos
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
GlobeNewsWire·11 hours ago
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
GlobeNewsWire·1 week ago
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fortress Biotech stock?
Fortress Biotech (FBIO) has a market cap of $59M as of June 09, 2025.
What is the P/E ratio for Fortress Biotech stock?
The price to earnings (P/E) ratio for Fortress Biotech (FBIO) stock is 0 as of June 09, 2025.
Does Fortress Biotech stock pay dividends?
No, Fortress Biotech (FBIO) stock does not pay dividends to its shareholders as of June 09, 2025.
When is the next Fortress Biotech dividend payment date?
Fortress Biotech (FBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Fortress Biotech?
Fortress Biotech (FBIO) has a beta rating of 1.77. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.